摘要
目的分析早期应用阿托伐他汀强化治疗急性心肌梗死的临床效果及安全性。方法选择在本院接受治疗的急性心肌梗死患者98例为研究对象,根据治疗方法不同分为对照组和观察组各49例,分别接受常规治疗及早期阿托伐他汀治疗,比较两组患者的临床疗效及治疗安全性差异。结果观察组患者治疗后胆固醇(TC)为(4.12±0.76)mmol/L,低密度脂蛋白(LDL)为(2.21±0.62)mmol/L、三酰甘油(TG)为(1.28±0.41)mmol/L,明显低于对照组的(4.98±1.04)、(2.89±0.78)、(1.54±0.63)mmol/L(P<0.05);高密度脂蛋白(HDL)为(1.13±0.22)mmol/L、一氧化氮(NO)为(84.21±18.43)mg/L,明显高于对照组的(1.02±0.14)mmol/L、(52.17±14.76)mg/L(P<0.05)。不良事件发生率(4.08%)明显低于对照组(16.32%)(P<0.05)。结论早期应用阿托伐他汀可以有效提高急性心肌梗死患者的治疗效果,且具有良好的治疗安全性。
Objective To analyze the clinical efficacy and safety of early intensive treatment with atorvastatin in acute myocardial infarction.Methods 98 cases of patients with acute myocardial infarction in our hospital were studied,and were divided into control group and observatino group according to the different therapy,the control group were treated with conventional therapy,the observatin group were treated with early atorvastatin therapy,the clinical efficacy and safe- ty of treatment was compared of two groups.Results TC was （4.12±0.76） mmol/L, LDL was （2.21±0.62） mmol/L,TG was （1.28±0.41） mmol/L in the observation group,was significantly lower than （4.98±1.04）,（2.89±0.78）,（1.54±0.63） mmol/L of the control group respectively （P〈0.05）.HDL was （1.13±0.22） mmol/L, NO was （84.21±18.43） mg/L in the observation group, was significantly higher than （1.02±0.14） mmol/L,（52.17±14.76） mg/L of the control group （P〈0.O5）.Incidenee of adverse events in observation group was 4.08%,was significantly lower than 16.32% of the control group （P〈O.OS）.Conclusion Early use of atorvastatin can effectively improve the treatment effect of patients with acute myocardial infarction,and also has good therapeutic safety.
出处
《中国当代医药》
2014年第2期61-62,共2页
China Modern Medicine
关键词
心肌梗死
阿托伐他汀
安全性
心力衰竭
Myocardial infarction
Atorvastatin
Security
Heart failure
